Assessment and treatment of airflow obstruction in patients with chronic obstructive pulmonary disorder: a guide for the clinician

References

• Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction: A clinicopathological study of patients in London and Chicago. Lancet. 1966;1:830–835.
   PubMed Web of Science ®Google Scholar
• Snider GL. Chronic obstructive pulmonary disease: a definition and implication of structural determinants of airflow obstruction for epidemiology. Am Rev Resp Dis. 1989;140(3 Pt 2):S3–8.
   PubMed Web of Science ®Google Scholar
• Janciauskiene SM, Bals R, Koczulla R, et al. The discovery of alfa-1-antitrypsin and its role in health and disease. Respir Med. 2011;105:1129–1139.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278:1355–1360.
   PubMed Web of Science ®Google Scholar
• Fisher BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance and inflammation. Int J Chron Obstruct Pulmon Dis. 2011;6:413–421.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small airways obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653.
   PubMed Web of Science ®Google Scholar
• Koo H-K, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross sectional study. Lancer Resp Med. 2018;6:591–602.
   PubMed Web of Science ®Google Scholar
• Takeyama K, Jung B, Shim JJ, et al. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoking. Am J Physiol Lung Cell Mol Physiol. 2001;280:L165–L172.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Carloni A, Rossi A, et al. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res. 2013;162:156–173.
   PubMed Web of Science ®Google Scholar
• Coppolino I, Ruggeri P, Nucera F, et al. Role of stem cells in the pathogenesis of chronic obstructive pulmonary disease and pulmonary emphysema. COPD. 2018;15:536–556.
   PubMedGoogle Scholar
• Lynch DA, Austin JHM, Hogg JC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the fleischner society. Radiology. 2015;277:192–205.
   PubMed Web of Science ®Google Scholar
• Kim WD, Eidelman DH, Izquierdo JL, et al. Centrilobular and panlobular emphysema in smokers: two distinct morphologic and functional entities. Am Rev Respir Dis. 1991;144:1385–1390.
   PubMed Web of Science ®Google Scholar
• Kim WD, Ling SH, Coxson HO, et al. The association between small airway obstruction and emphysema phenotypes in COPD. Chest. 2007;131:1372–1378.
   PubMed Web of Science ®Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365:1567–1575.
   PubMed Web of Science ®Google Scholar
• Boes JL, Hoff BA, Bule M, et al. Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). Acta Radiol. 2015;22:186–194.
   Google Scholar
• Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:178–184.
   PubMed Web of Science ®Google Scholar
• Tanabe N, Vasilescu DM, Hague CJ, et al. Pathological comparisons of paraseptal and centrilobular emphysema in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202:803–811.
   PubMed Web of Science ®Google Scholar
• Hobbs BD, Foreman MG, Bowler R, et al. COPDGene Investigators. Pneumothorax risk factors in smokers with and without chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1387–1394.
   PubMedGoogle Scholar
• Tiffeneau R, Pinelli. Air circulant et air captif dans l’l’exploration de la fonction ventilatrice pulmonaire. Paris Med. 1947;37:624–628.
   PubMedGoogle Scholar
• Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS task force. Standardization of spiromtery. Eur Respir J. 2005;26:319–338.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function test. Eur Respir J. 2005;26:948–968.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention. A guide for health care professionals 2017; [cited 2017 May 3]. Available from: http://oldcopd.org/wp-content/uploads/2016/12/wsm-GOLD-2017-Pocketguide.pdf
   Google Scholar
• Enright P, Brusasco V. Counterpoint: should we abandon FEV1/FVC <0.70 to detect airway obstruction? Yes. Chest. 2010;138:1040–1042.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418–424.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Pini L. COPD: it is time to change! Int J Chron Obstruct Pulmon Dis. 2015;10:2451–2457.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med. 2004;350:10–19.
   Web of Science ®Google Scholar
• Divo M, Cote CG, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:756–762.
   Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181–191.
   PubMed Web of Science ®Google Scholar
• Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. Epub 2012 May 18.
   PubMed Web of Science ®Google Scholar
• Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67:701–708.
   PubMed Web of Science ®Google Scholar
• Perng DW, Huang HY, Cheng H-M, et al. Characteristics of airway inflammation and bronchodilator reversibility in COPD. A potential guide to treatment. Chest. 2004;126:375–381.
   PubMed Web of Science ®Google Scholar
• Sitkauskiene B, Sakalauskas R, Malakauskas K, et al. Reversibility to a beta-2 agonist in COPD: relationship to atopy and neutrophil activation. Resp Med. 2003;97:591–598.
   PubMed Web of Science ®Google Scholar
• Cerveri I, Pellegrino R, Dore R, et al. Mechanisms for isolated volume response to bronchodilator in patients with COPD. J Appl Physiol. 2000;88:1989–1995.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease. Eur Respir J. 1998;12:799–804.
   PubMed Web of Science ®Google Scholar
• Hadcroft J, Calverley PMA. Alternative methods to assess bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax. 2001;56:713–720.
   PubMed Web of Science ®Google Scholar
• Newton MF, O’Donnell DE, Forkert I. Response of lung volume to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002;121:1042–1050.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770–777.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Hyperinflation, dyspnea and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180–184.
   PubMedGoogle Scholar
• Tantucci C. Expiratory flow limitation: definition, mechanisms, methods and significance. Pulm Med. 2013;2013:749860. Epub 2013 Mar 28.
   PubMedGoogle Scholar
• Calverley PMA, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J. 2005;25:186–199.
   PubMed Web of Science ®Google Scholar
• Koulouris NG, Valta P, Lavoie A, et al. A simple method to detect expiratory flow limitation during spontaneous breathing. Eur Respir J. 1995;8:306–313.
   PubMed Web of Science ®Google Scholar
• Ninane V, Leduc D, Kafi SA, et al. Detection of expiratory flow limitation by manual compression of abdominal wall. Am J Respir Crit Care Med. 2001;163: 13326–1330.
   PubMed Web of Science ®Google Scholar
• Dellacà RL, Santus P, Aliverti A, et al. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004;23:232–240.
   PubMed Web of Science ®Google Scholar
• Koulouris NG, Dimopoulou I, Valta P, et al. Detection of expiratory flow limitation during exercise in COPD patients. J Appl Physiol. 1997;82:723–731.
   PubMed Web of Science ®Google Scholar
• Chiari S, Bassini S, Braghini A, et al. Tidal expiratory flow limitation at rest as a functional marker of pulmonary emphysema in moderate-to.severe COPD. COPD. 2014;11:33–38.
   PubMedGoogle Scholar
• O’Donnell DE, Webb K. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. (1985) 2008;105:753–755.
   PubMed Web of Science ®Google Scholar
• Eltayara L, Becklake MR, Volta CA, et al. Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:1726–1734.
   PubMed Web of Science ®Google Scholar
• Aarli BB, Calverley PMA, Jensen RJ, et al. The association of tidal EFL with exercise performance, exacerbations, and death in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2179–2188.
   PubMed Web of Science ®Google Scholar
• Baldi S, Dellacà R, Govoni L, et al. Airway distensibility and volume recruitment with lung inflation in COPD. J Appl Physiol. (1985) 2010;109: 1019–1026.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Seemungal AR. The role of bronchodilator treatment in the prevention of exacerbation of COPD. Eur Respir J. 2012;40:1545–1554.
   PubMed Web of Science ®Google Scholar
• Beeh KW, Burgel P-R, Franssen FME, et al. How dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2017;196:139–149.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Pini L. Inhaled corticosteroids in COPD: trying to make along story short. Int J Chron Obstruct Pulmon Dis. 2020;15:821–829.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhong N, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. New Engl J Med. 2017;377(10):923–935.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta-2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–973.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. IMPACT investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18): 16712–1680. DOI:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Boni E, Corda L, Franchini D, et al. Volume effect and exertional dyspnea after bronchodilator in COPD patients with and without expiratory flow limitation at rest. Thorax. 2002;57:528–532.
   PubMed Web of Science ®Google Scholar
• Miravittles M, Worth H, Soler-Cataluna J, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122–135.
   PubMed Web of Science ®Google Scholar
• Uccelli S, Pini L, Bottone D, et al. Dyspnea during night-time and at early morning in patients with stable COPD is associated with supine tidal expiratory flow limitation. Int J Chron Obstruct Pulmon Dis. 2020;15:2549–2558.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicenter randomised studies (ACLIFORM and AUGMENT). Resp Res. 2015;16:92–105.
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, et al. National emphysema treatment trial research group. A randomized trial comparing lung volume reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–2073.
   PubMed Web of Science ®Google Scholar
• Sciurba FC, Ernst A, Herth FJF, et al. VENT study research group. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363:1233–1244.
   PubMed Web of Science ®Google Scholar
• Herth FJ, Noppen M, Valipur A, et al. Internation VENT study group. Efficacy predictors of lung volume reduction with Zephir valves in a European cohort. Eur Respir J. 2012;39:1334–1342.
   PubMed Web of Science ®Google Scholar
• Valipour A, Herth FJ, Burghuber OC, et al. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. Eur Respir J. 2014;43(2):387–396.
   PubMed Web of Science ®Google Scholar
• Valipur A, Slebos DJ, Herth FJ, et al. IMPACT study team. Endobronchial valve therapy in patients with homogeneous emphysema: results from the IMPACT study. Am J Respir Crit Care Med. 2016;194:1073–1082.
   PubMed Web of Science ®Google Scholar
• Kemp SV, Slebos DJ, Kink A, et al. A multicenter randomized controlled trial of Zephir endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196:1535–1543.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogeneous emphysema with the spiration valve system (IMPROVE). A multicenter, open-label, randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200:1354–1362.
   PubMed Web of Science ®Google Scholar